ArticleProceedings of the National Academy of Sciences of the United States of America2007

TLR9 agonist acts by different mechanisms synergizing with bevacizumab in sensitive and cetuximab-resistant colon cancer xenografts.

Vincenzo Damiano et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.